FDA accepts Cogent’s bezuclastinib NDA in nonadvanced SM: full analysis

CURRENT FULL VERSION: Cogent Biosciences has cleared an important regulatory step for bezuclastinib, with the US FDA accepting the company’s NDA for adults with nonadvanced systemic mastocytosis and setting a PDUFA target action date of December 30, 2026. According to company-reported details carried by multiple trade outlets, the FDA also said it doesn’t currently plan to convene an advisory committee and hasn’t identified preliminary review issues, giving the program a cleaner-than-feared start to formal review. (stocktitan.net)

This acceptance follows a series of positive updates from Cogent’s SUMMIT program. In July 2025, the company reported top-line data showing statistically significant results across the primary and key secondary endpoints, then presented fuller results in December 2025 at ASH. Those data positioned bezuclastinib as a potential disease-modifying therapy in a population with limited targeted treatment options, particularly for patients with indolent, smoldering, or bone marrow mastocytosis captured under the NonAdvSM umbrella. (investors.cogentbio.com)

The key clinical details have stayed consistent across Cogent’s disclosures. SUMMIT was a randomized, global, placebo-controlled, registration-directed Phase 2 study in patients with moderate to severe NonAdvSM. Trade coverage of the acceptance said the trial met its 24-week primary endpoint on total symptom score and all key secondary endpoints, including at least 50% reductions in serum tryptase, KIT D816V variant allele fraction, and bone marrow mast cell burden. Cogent has also highlighted 48-week follow-up data suggesting symptomatic improvement deepened over time, alongside a safety and tolerability profile the company believes could support chronic use. (hcplive.com)

The broader regulatory backdrop also matters. Cogent disclosed in its 2025 annual report that it submitted the NonAdvSM NDA in December 2025, expects an NDA filing in advanced systemic mastocytosis in the first half of 2026, and began its GIST NDA process in January 2026 with completion expected in April 2026. Additional trade reporting fills in more of that GIST picture: the company said FDA has received an NDA under the Real-Time Oncology Review program for bezuclastinib in previously treated GIST, supported by the phase 3 PEAK trial comparing bezuclastinib plus sunitinib with sunitinib monotherapy. According to that report, the study met its primary endpoint with a 50% improvement in progression-free survival, with median PFS of 16.5 months versus 9.2 months, and showed an objective response rate of 46% versus 26%; full data presentation is expected in the first half of 2026. Cogent also said the combination is moving into phase 2 for treatment-naive or imatinib-experienced first-line GIST with exon 9 mutations, and that FDA-aligned expanded access programs are in place for eligible US patients with GIST or systemic mastocytosis receiving bezuclastinib-based therapies. (sec.gov) (pharmashots.com)

The company also said FDA granted Breakthrough Therapy Designation in October 2025 for bezuclastinib in certain NonAdvSM populations, including previously treated patients and those with smoldering systemic mastocytosis, and that both FDA and EMA have granted orphan drug designation in mastocytosis. (sec.gov)

Outside the company, specialist trade outlets framed the acceptance as potentially significant because bezuclastinib could become the first therapy specifically targeting KIT D816V in the nonadvanced setting if approved. In Cogent’s December 2025 ASH release, Duke hematologist Lindsay Rein, MD, said patients with NonAdvSM have “very limited treatment options” and called the benefit seen across disease pathology and symptomatic improvement “very exciting” for this population. That’s still company-linked commentary rather than independent peer-reviewed editorial reaction, but it underscores the unmet need narrative around the program. (hcplive.com)

Why it matters: For veterinary professionals, this is mainly a translational and market-intelligence story rather than a practice-changing one. Mast cell disease, KIT signaling, and targeted kinase inhibition remain highly relevant concepts across species, and regulatory progress in human mast cell disorders can influence comparative oncology thinking, investor attention, and future drug-development strategies. The added GIST filing context also suggests Cogent is positioning bezuclastinib as a broader KIT-focused oncology franchise rather than a single-indication asset. It’s also a reminder that regulators are increasingly willing to consider applications supported by symptom improvement plus biomarker change, especially in rare diseases where treatment options are thin. Still, approval isn’t guaranteed: Cogent’s own SEC filing emphasizes commercial, safety, payer, and adoption risks, even if the review has started on solid footing. (sec.gov)

What to watch: The immediate watchpoint is whether the FDA review stays on track through December 30, 2026, and whether Cogent can deliver its planned GIST and AdvSM filings on time. Also worth watching are the expected fuller PEAK data in the first half of 2026 and the company’s next-step study in first-line exon 9-mutant GIST, which together would make 2026 a pivotal regulatory and clinical year for the bezuclastinib franchise. (stocktitan.net) (pharmashots.com)